OErsted A/S

  • ISIN: XS0253170335
  • Land: .

Nachricht vom 13.02.2018 | 10:25

Notice for the Annual General Meeting of OErsted A/S

OErsted A/S (65XG)

13-Feb-2018 / 10:25 CET/CEST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


The Annual General Meeting of Ørsted A/S will be held on Thursday 8 March 2018 at 10:00 CET.

The Annual General Meeting will be held at Comwell Conference Center Copenhagen, Center Boulevard 5, Entrance 1, DK-2300 Copenhagen S, Denmark.

The notice for the Annual General Meeting is enclosed.

The information provided in this announcement does not change Ørsted’s previous financial guidance for the 2018 financial year.

Further information

Media Relations
Tom Lehn-Christiansen
+45 99 55 60 17

Investor Relations
Henrik Brünniche Lund
+45 99 55 97 22


About Ørsted

The Ørsted vision is a world that runs entirely on green energy. Ørsted develops, constructs and operates offshore wind farms, bioenergy plants and innovative waste-to-energy solutions and provides smart energy products to its customers. Headquartered in Denmark, Ørsted employs 5,600 people. Ørsted's shares are listed on Nasdaq Copenhagen (Orsted). In 2017, the group's revenue was DKK 59.5 billion (EUR 8.0 billion). For more information on Ørsted, visit https://orsted.com/ or follow us on Facebook, LinkedIn, Instagram and Twitter.

 

Click on, or paste the following link into your web browser, to view the associated documents https://cns.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=663326 https://cns.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=663327



show this

GBC im Fokus

M1 Kliniken: Geschäftsjahr über den Erwartungen

Mit dem deutlichen Anstieg auf 21 Klinikstandorte (Ende 2016: 13) hat die auf ästhetische Medizin spezialisierte M1 Kliniken AG die Basis für einen Ausbau der Umsatz- und Ertragsbasis gelegt. Hinzu kommt die bereits in Umsetzung befindliche Erschließung weiterer Umsatzströme, wie etwa die Erweiterung der Eigenmarken oder die Abdeckung der ästhetischen Zahnmedizin. Das Kursziel beläuft sich auf 18,50 € und das Rating lautet KAUFEN.

Aktueller Webcast

EQS Group AG

Q3-report 2018

18. Mai 2018

Aktuelle Research-Studie

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): BUY Valneva SE

22. Mai 2018